智通财经APP获悉，和铂医药-B(02142)早盘涨超7%，截至发稿，涨7.23%，报13.65港元，成交额3403.36万港元。
消息面上，和铂医药近日发布盈喜，预计2026上半年实现营业收入1.2-1.25亿美元；期内净利0.62-0.67亿美元。主要源于与全球跨国药企达成的持续战略合作；创新产品对外授权及合作确认收入款项；诺纳生物抗体相关业务实现强劲增长。
值得注意的是，7月公司与国药集团签署战略合作，以建立国药集团-和铂医药创新联合体，并就创新型生物药的研发领域开展合作，战略重点覆盖肿瘤及免疫炎症等疾病领域。根据协议双方将共同承担研发成本、共同享有产品权益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.